SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001000694-24-000003
Filing Date
2024-01-31
Accepted
2024-01-31 08:00:41
Documents
14
Period of Report
2024-01-30
Items
Item 2.05: Cost Associated with Exit or Disposal Activities

Document Format Files

Seq Description Document Type Size
1 8-K nvax-20240130.htm   iXBRL 8-K 35491
  Complete submission text file 0001000694-24-000003.txt   161413

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nvax-20240130.xsd EX-101.SCH 1914
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nvax-20240130_lab.xml EX-101.LAB 23834
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nvax-20240130_pre.xml EX-101.PRE 12520
15 EXTRACTED XBRL INSTANCE DOCUMENT nvax-20240130_htm.xml XML 2712
Mailing Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878
Business Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

IRS No.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 24580673
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)